Ehab L. Atallah, MD, Medical College of Wisconsin, Milwaukee, WI, and Michael J. Mauro, MD, Memorial Sloan Kettering Cancer Center, New York, NY, reviewed first- and second-generation TKIs, as well as emerging therapies for CML and their side effects. Dr Mauro discussed the need to develop additional guidelines for cessation of treatment in patients in remission.